Contents

Search

BRAF V600K mutation

Indications: - elibigiblity for treatment of metastatic melanoma with trametinib (Mekinist) Procedure: - polymerase chain reaction to identify point mutation Val-600 to Lys-600 in the BRAF gene Clinical significance: - mutation present in late-stage melanomas

Related

cutaneous melanoma serine/threonine protein kinase B-raf; proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1 (BRAF BRAF1 RAFB1)

General

BRAF V600 mutation (THxID BRAF)

References

  1. FDA News Release: May 29, 2013 FDA approves two drugs, companion diagnostic test for advanced skin cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199